Advanced Relief for Treatment-Resistant Depression

When previous antidepressant treatments have not provided enough relief, a clinical evaluation helps determine whether SPRAVATO® is an appropriate next step. SPRAVATO® is an FDA-approved prescription esketamine nasal spray for adults with treatment-resistant depression, used alone or with an oral antidepressant.

Patients self-administer the spray under direct healthcare supervision at a certified treatment center. Each session includes at least two hours of monitoring for side effects, including sedation, dissociation, breathing problems, and changes in blood pressure. Patients must arrange transportation home and avoid driving until the next day after restful sleep.

Treatment begins with a review of your symptoms, medical history, and previous care. Your provider will discuss benefits, risks, and treatment expectations with you.